The European Commission has recently published a comprehensive package of regulatory reforms for the pharmaceutical sector in the European Union (EU), setting out a legislative action plan and strategic vision that seeks to balance greater patient access, improved regulatory efficiency, and the need to boost the Life Sciences sector’s global competitiveness. Join us, Tim Wilsdon and Anthony Barron, as we explore some of the key components of the new Pharmaceutical Strategy for Europe and set out some of the policy initiatives stemming from the strategy.
Part 4: Inflation Reduction Act: The indirect effects and implications of IRA price negotiations
Since passage of the Inflation Reduction Act (IRA) in August 2022, the focus of many industry analysts and pharmaceutical companies has been on two important...